In contrast to these results, a study using nationwide registry data from Sweden, Denmark, and Norwayinvolving 121,254 new GLP-1 RA users and 185,027 new SGLT-2 inhibitor users documented 557 intestinal obstruction events, with no significant correlation between GLP-1 RA use and increased intestinal obstruction risk, thereby refuting earlier safety concerns [12]
In fact, the GLP-1 market was valued at $16.53 billion in 2021 and is expected to reach a whopping $24.10 billion by 2027
Obesity and Overweight: Many people use Semaglutide for weight management
The choice isn't "GLPatch or injections" anymore - it's a three-way evaluation: prescription oral GLP-1 drug (via a provider, with clinical data, at prescription cost), botanical supplement patch (no prescription, different evidence standard, lower cost, different mechanism), or nothing
While GLP-1 Support Supplement options may seem appealing, it's important to have a deeper understanding of what these products can actually do
These developments are important here in Charlotte, where nearly 35% of adults have a Body Mass Index (BMI) of 30 or higher, classifying them as obese